$3.66
1.61% yesterday
Nasdaq, Dec 02, 10:14 pm CET
ISIN
US29664W1053
Symbol
ESPR

Esperion Therapeutics, Inc. Stock price

$3.66
+0.71 24.07% 1M
+2.74 298.43% 6M
+1.46 66.36% YTD
+0.56 18.06% 1Y
-3.73 50.47% 3Y
-26.06 87.69% 5Y
-26.16 87.73% 10Y
-10.84 74.76% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.06 1.61%
ISIN
US29664W1053
Symbol
ESPR
Industry

Key metrics

Basic
Market capitalization
$875.0m
Enterprise Value
$1.1b
Net debt
$211.2m
Cash
$92.5m
Shares outstanding
205.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.9 | 2.2
EV/Sales
3.6 | 2.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-113.1%
Return on Equity
13.3%
ROCE
-588.8%
ROIC
-42.9%
Debt/Equity
-0.7
Financials (TTM | estimate)
Revenue
$303.8m | $394.9m
EBITDA
$-29.3m | $-57.7m
EBIT
$-29.4m | $81.6m
Net Income
$-105.8m | $-1.5m
Free Cash Flow
$-93.3m
Growth (TTM | estimate)
Revenue
2.8% | 18.8%
EBITDA
-277.5% | -206.0%
EBIT
-278.5% | 50.1%
Net Income
-22.0% | 97.2%
Free Cash Flow
-257.7%
Margin (TTM | estimate)
Gross
58.2%
EBITDA
-9.6% | -14.6%
EBIT
-9.7%
Net
-34.8% | -0.4%
Free Cash Flow
-30.7%
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
10.6%
Employees
304
Rev per Employee
$1.1m
Show more

Is Esperion Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Esperion Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Esperion Therapeutics, Inc. forecast:

10x Buy
71%
3x Hold
21%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Esperion Therapeutics, Inc. forecast:

Buy
71%
Hold
21%
Sell
7%

Financial data from Esperion Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
304 304
3% 3%
100%
- Direct Costs 127 127
133% 133%
42%
177 177
27% 27%
58%
- Selling and Administrative Expenses 161 161
6% 6%
53%
- Research and Development Expense 45 45
15% 15%
15%
-29 -29
278% 278%
-10%
- Depreciation and Amortization 0.11 0.11
175% 175%
0%
EBIT (Operating Income) EBIT -29 -29
279% 279%
-10%
Net Profit -106 -106
22% 22%
-35%

In millions USD.

Don't miss a Thing! We will send you all news about Esperion Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Esperion Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
12 days ago
Esperion Therapeutics, Inc. ( ESPR ) Jefferies London Healthcare Conference 2025 November 18, 2025 3:00 AM EST Company Participants Benjamin Halladay - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morning. Welcome to the Jefferies London Healthcare Conference.
Neutral
GlobeNewsWire
15 days ago
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk ...
Positive
Seeking Alpha
21 days ago
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.
More Esperion Therapeutics, Inc. News

Company Profile

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Head office United States
CEO Sheldon Koenig
Employees 304
Founded 1998
Website www.esperion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today